News | April 09, 2015

Medtronic Enrolls First Patient in GOLD AF Registry Study

Study will explore procedural use and treatment outcomes with Medtronic’s Phased RF ablation technology in treating atrial fibrillation

Medtronic, GOLD AF Registry, PVAC GOLD, atrial fibrillation, ablation catheter

April 9, 2015 — Medtronic plc announced the first patient enrollment in the GOLD AF Registry, a prospective, observational clinical study of its Phased Radiofrequency (RF) Ablation technology for treating patients with symptomatic atrial fibrillation (AF). The multicenter registry will provide real-world insights into the procedural use and treatment outcomes of the Pulmonary Vein Ablation Catheter (PVAC) GOLD, multi-electrode ablation catheter and other catheters that comprise Medtronic's Phased RF technology.

The Medtronic Phased RF System is a generator and endocardial catheter system that delivers customized RF energy to eliminate or block abnormal electrical impulses in the left atrium that initiate or sustain AF. The system is not approved in the United States, but is under investigational device exemption (IDE) study in the VICTORY AF clinical trial.

"The GOLD AF Registry will give us the opportunity to further evaluate and uncover best practices for treating patients with Phased Radiofrequency technology," said L.V.A. Boersma, M.D., cardiologist at St. Antonius Ziekenhuis Nieuwegein, The Netherlands. "We'll be able to review data - in a very large patient cohort - on the PVAC GOLD catheter, which maps, ablates and validates pulmonary vein isolation quickly. Pulmonary vein isolation is a clinically effective therapy for treating symptomatic AF patients, and the goal of the PVAC GOLD catheter is to allow physicians to effectively isolate the veins."

The GOLD AF Registry will assess treatment by PVAC GOLD ablation of patients with paroxysmal (occasional) or persistent AF, lone AF or AF with underlying disease, and provide data on acute and mid-term success rates, as well as other procedural details and patient characteristics. It will enroll up to 1,000 patients at 50 sites in 11 countries. Patients will be observed for 12 months following a Phased RF procedure.

The PVAC GOLD catheter features improved thermal efficiency of gold electrodes, compared to the platinum electrodes of the first-generation system, to help physicians optimize RF ablation therapy. By delivering RF energy through nine electrodes (either all simultaneously or a subset of electrodes), the PVAC GOLD catheter helps physicians safely and efficiently create consistent lesions (intentional scar in the tissue) to effectively block the erratic AF electrical currents coming from the pulmonary veins. The gold electrodes provide four times the thermal conductivity of their platinum predecessors, offering the potential for more accurate temperature measurement and improved power delivery.

The catheter features an over-the-wire design and an anatomic shape to help physicians safely position and stabilize the catheter in different patient anatomies. A forward-tilted array helps physicians find optimal placement that is designed to improve uniformity of contact with the tissue. Following ablation, the catheter is capable of verifying PV isolation through its ability to pace and map.

For more information:

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve